###begin article-title 0
Oct-4 Expression Maintained Cancer Stem-Like Properties in Lung Cancer-Derived CD133-Positive Cells
###end article-title 0
###begin p 1
Conceived and designed the experiments: SHC YCC HSH YWC THT SCH HHK. Performed the experiments: SHC YCC HSH YWC CKH MLT. Analyzed the data: SHC YCC HSH YWC THT CYW SCH HHK. Contributed reagents/materials/analysis tools: SHC YCC HSH YWC THT CKH CYW SCH YLC YYL HHK. Wrote the paper: SHC.
###end p 1
###begin p 2
###xml 236 237 236 237 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 273 274 273 274 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 381 382 381 382 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 563 564 563 564 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 581 582 581 582 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 879 880 879 880 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 932 933 932 933 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 964 965 964 965 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1022 1023 1022 1023 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1201 1209 1201 1209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1214 1221 1214 1221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1305 1306 1305 1306 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1528 1529 1528 1529 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1618 1619 1618 1619 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 303 311 <span type="species:ncbi:9606">patients</span>
CD133 (prominin-1), a 5-transmembrane glycoprotein, has recently been considered to be an important marker that represents the subset population of cancer stem-like cells. Herein we report the isolation of CD133-positive cells (LC-CD133+) and CD133-negative cells (LC-CD133-) from tissue samples of ten patients with non-small cell lung cancer (LC) and five LC cell lines. LC-CD133+ displayed higher Oct-4 expressions with the ability to self-renew and may represent a reservoir with proliferative potential for generating lung cancer cells. Furthermore, LC-CD133+, unlike LC-CD133-, highly co-expressed the multiple drug-resistant marker ABCG2 and showed significant resistance to chemotherapy agents (i.e., cisplatin, etoposide, doxorubicin, and paclitaxel) and radiotherapy. The treatment of Oct-4 siRNA with lentiviral vector can specifically block the capability of LC-CD133+ to form spheres and can further facilitate LC-CD133+ to differentiate into LC-CD133-. In addition, knock-down of Oct-4 expression in LC-CD133+ can significantly inhibit the abilities of tumor invasion and colony formation, and increase apoptotic activities of caspase 3 and poly (ADP-ribose) polymerase (PARP). Finally, in vitro and in vivo studies further confirm that the treatment effect of chemoradiotherapy for LC-CD133+ can be improved by the treatment of Oct-4 siRNA. In conclusion, we demonstrated that Oct-4 expression plays a crucial role in maintaining the self-renewing, cancer stem-like, and chemoradioresistant properties of LC-CD133+. Future research is warranted regarding the up-regulated expression of Oct-4 in LC-CD133+ and malignant lung cancer.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 94 97 94 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Spira1">[1]</xref>
###xml 99 102 99 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Hsu1">[2]</xref>
###xml 246 249 246 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Socinski1">[3]</xref>
###xml 251 254 251 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Bernstein1">[4]</xref>
###xml 408 411 408 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Lam1">[5]</xref>
###xml 534 537 534 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Lam1">[5]</xref>
###xml 788 791 788 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Jordan1">[6]</xref>
###xml 918 921 918 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Goodell1">[7]</xref>
###xml 1192 1195 1192 1195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Ho1">[8]</xref>
###xml 1430 1433 1430 1433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Gutova1">[9]</xref>
###xml 229 236 <span type="species:ncbi:9606">patient</span>
###xml 330 338 <span type="species:ncbi:9606">patients</span>
###xml 428 435 <span type="species:ncbi:9606">patient</span>
###xml 986 991 <span type="species:ncbi:9606">human</span>
Lung cancer is one of the leading causes of cancer-related deaths in industrialized countries [1], [2]. Radiotherapy and chemotherapy play significant and crucial roles in clinical anti-lung cancer treatment to achieve prolonged patient survival [3], [4]. However, a high failure rate and low median survival rate are observed in patients undergoing chemoradiotherapy with recurrent, intractable lung cancer [5]. To improve the patient survival rate, investigation to elucidate the mechanism of tumorigenesis of lung cancer is needed [5]. Recent data have demonstrated that tumors contain a small subpopulation of cells, i.e., cancer stem-like cells (CSCs) or cancer-initiating cells (CICs), which exhibit a self-renewing capacity and are responsible for tumor maintenance and metastasis [6]. Stem cells have been isolated by their ability to efflux Hoechst 33342 dye and are referred to as the "side population (SP)" [7]. Ho and colleagues isolated and characterized SP cells from six human lung cancer cell lines and showed that an elevated expression of ABCG2 as well as other ATP-binding cassette transporters were positively correlated with resistance to multiple chemotherapeutic drugs [8]. In addition, Gutova and colleagues have purified uPAR-positive CSCs from three lung cancer cell lines. These uPAR-positive cells co-expressed with CD44 and MDR1, and had the ability to promote advanced malignancy and chemoresistance [9].
###end p 4
###begin p 5
###xml 80 81 80 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 158 162 158 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Yin1">[10]</xref>
###xml 405 409 405 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Collins1">[11]</xref>
###xml 410 414 410 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Bruno1">[19]</xref>
###xml 512 513 512 513 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 636 640 636 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Hilbe1">[20]</xref>
###xml 757 758 757 758 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 854 855 854 855 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 910 914 910 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Eramo1">[21]</xref>
###xml 587 595 <span type="species:ncbi:9606">patients</span>
CD133 (prominin-1), a 5-transmembrane glycoprotein, was first recognized in CD34+ progenitor populations from adult blood, bone marrow, and fetal liver cells [10]. Recently, CD133 has been considered an important marker to represent the subset population of CSCs in leukemia, brain tumors, retinoblastoma, renal tumors, pancreatic tumors, colon carcinoma, prostate carcinoma, and hepatocellular carcinoma [11]-[19]. Based on immunohistochemical findings, Hilbe and colleagues suggested that CD133-positive (CD133+) progenitor cells play a role in the development of tumor vasculature in patients with non-small-cell lung cancer (NSCLC) [20]. More recently, a well-designed study by Eramo and colleagues showed that lung cancer contains a population of CD133+ CSCs able to self-renew and generate an unlimited progeny of non-tumorigenic cells. These CD133+ cells are also resistant to conventional chemotherapy [21]. However, the gene regulation mechanisms in maintaining the self-renewal and drug-resistant properties in putative cancer stem-like cells of lung tumors are still unclear.
###end p 5
###begin p 6
###xml 130 134 130 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Rosner1">[22]</xref>
###xml 135 139 135 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Burdon1">[23]</xref>
###xml 238 242 238 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Boiani1">[24]</xref>
###xml 261 266 261 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Oct-4</italic>
###xml 412 416 412 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Nichols1">[25]</xref>
###xml 536 541 536 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fgf 4</italic>
###xml 575 579 575 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pdgf</italic>
###xml 584 585 580 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 634 638 626 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Lamb1">[26]</xref>
###xml 640 644 632 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Kraft1">[27]</xref>
###xml 838 842 830 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Boiani1">[24]</xref>
###xml 844 848 836 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Nichols1">[25]</xref>
###xml 275 279 <span type="species:ncbi:10090">mice</span>
Oct-4, a member of the family of POU-domain transcription factors, is expressed in pluripotent embryonic stem (ES) and germ cells [22]-[23]. Oct-4 mRNA is normally found in totipotent and pluripotent stem cells of pregastrulation embryos [24]. Knocking out the Oct-4 gene in mice causes early lethality due to the lack of ICM formation, indicating that Oct-4 has a critical function for self-renewal of ES cells [25]. Oct-4 activates transcription via octamer motifs, and Oct-4 binding sites have been found in various genes, including fgf 4 (fibroblast growth factor 4) and pdgfalphar (platelet-derived growth factor alpha receptor) [26], [27]. This suggests that Oct-4 functions as a master switch during differentiation by regulating the pluripotent potentials of the stem cell, and Oct-4 plays a pivotal role in mammalian development [24], [25].
###end p 6
###begin p 7
###xml 49 50 49 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 86 87 86 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 185 186 185 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 332 333 332 333 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 635 636 635 636 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 143 151 <span type="species:ncbi:9606">patients</span>
In this study, the CD133-positive cells (LC-CD133+) and CD133-negative cells (LC-CD133-) were isolated from tissue samples of lung cancer (LC) patients and LC cell lines. These LC-CD133+ cells possessed both the characteristics of stem-like cells and malignant tumors. Our data further demonstrated that Oct-4 expression in LC-CD133+ is involved in tumor malignancy of lung cancers and exhibits refractory properties for chemoradiotherapy in cancer stem-like cells. These results suggested that the expression of Oct-4 plays a crucial role in maintaining cancer stem-like and chemoradioresistant properties in lung cancer-derived CD133+ cells.
###end p 7
###begin title 8
Materials and Methods
###end title 8
###begin title 9
###xml 18 19 18 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Isolation of CD133+ Cell Subset
###end title 9
###begin p 10
###xml 341 348 341 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002637-t001">Table 1</xref>
###xml 529 530 529 530 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 752 756 752 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Chiou1">[28]</xref>
###xml 101 109 <span type="species:ncbi:9606">patients</span>
###xml 331 339 <span type="species:ncbi:9606">patients</span>
###xml 684 689 <span type="species:ncbi:9606">human</span>
This research followed the tenets of the Declaration of Helsinki and all samples were obtained after patients provided informed consent. The study was approved by the Institutional Ethics Committee/Institutional Review Board of Taipei Veterans General Hospital. The dissociated cells from the samples of non-small cell lung cancer patients (Table 1) and the lung cancer (LC) cell lines were labeled with 1 mL CD133/l micromagnetic beads per 1 million cells using the CD133 cell isolation kit (Miltenyi Biotech, Auburn, CA). CD133+ cells were cultured in a medium consisting of serum-free DMEM/F12 (Gibco-BRL, Gaithersburg, MD), N2 supplement (R&D Systems Inc., Minneapolis), 10 ng/ml human recombinant bFGF (R&D Systems) and 10 ng/ml EGF (R&D Systems) [28].
###end p 10
###begin title 11
###xml 38 39 38 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 49 50 49 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 112 113 112 113 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
The tumor formation abilities of CD133+ and CD133- in NSCLC description and tumorigenic characteristics of CD133+
###end title 11
###begin p 12
###xml 5 6 5 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 16 17 16 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 65 69 <span type="species:ncbi:10090">mice</span>
###xml 272 276 <span type="species:ncbi:10090">mice</span>
CD133+ and CD133- cells were injected into the tail vein of SCID mice, respectively. NSCLC: non-small cell lung cancer. SF: sphere formation. AC: adenocarcinoma. SCC: squamous cell carcinoma. Positive response (Positivity): the tumor formation in the lung tissues of SCID mice. Sphere Formation: Under serum-free medium with bFGF & EGF culture for 4 weeks.
###end p 12
###begin title 13
Cell Viability Determined by Colorimetric Assay
###end title 13
###begin p 14
###xml 18 19 18 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 29 30 29 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 133 134 133 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 567 568 553 554 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
The isolated CD133+ and CD133- cells were cultured in a 96-well cell culture cluster (Corning Costar, Acton, MA) at a density of 3x103 cells/well with 100 microl culture medium. At specific time points during cultivation, the medium was discarded and replaced with an equal volume (100 microl) of fresh medium containing 0.2 mg/ml of 3- (4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS, Promega, Madison, WI) and 0.038 mg/ml of phenazine methosulfate (PMS; Promega) and incubated for additional 1.5 hours in 37degreesC 5% CO2. Cell viability proportionate to optical density (OD) was measured by colorimetric assay in terms of mitochondria activity to convert tetrazolium salt into a colored soluble formazan product in the medium. The OD values were measured at the wavelength of 490 nm with a 1420 multilabel counter VICTOR from Wallac (PerkinElmer Wallac, Turku, Finland).
###end p 14
###begin title 15
Real-time Reverse Transcription-polymerase Chain Reaction (RT-PCR)
###end title 15
###begin p 16
###xml 84 88 84 88 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">easy</sub>
###xml 402 403 382 383 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 795 813 767 785 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GCCAAAAGGGTCATCATC</named-content>
###xml 871 892 843 864 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">ATGACCTTGCCCACA GCCTT</named-content>
###xml 918 936 890 908 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">CGCAAGCCCTCATTTCAC</named-content>
###xml 992 1010 964 982 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">CATCACCTCCACCACCTG</named-content>
For real-time RT-PCR analysis, the total RNA of cells was extracted by using the RNAeasy kit (Qiagen, Valencia, CA). Briefly, the total RNA (1 microg) of each sample was reversely transcribed in 20 microL using 0.5 microg of oligo dT and 200 U Superscript II RT (Invitrogen, Carlsbad, CA). The amplification was carried out in a total volume of 20 microl containing 0.5 microM of each primer, 4 mM MgCl2, 2 microl LightCycler FastStart DNA Master SYBR green I (Roche Diagnostics, Pleasanton, CA) and 2 microl of 1:10 diluted cDNA. The quantification of the unknown samples was performed by LightCycler Relative Quantification Software, version 3.3 (Roche Diagnostics). In each experiment, the GAPDH housekeeping gene was amplified as a reference standard. GAPDH primers were designed: GAPDH(f): GCCAAAAGGGTCATCATC (nt 448-465, GenBank accession no. NM_002046), GAPDH(r): ATGACCTTGCCCACA GCCTT (nt 745-765), Oct-4a(f): CGCAAGCCCTCATTTCAC (nt 5-22, GenBank accession no. NM_002701), Oct-4a(r): CATCACCTCCACCACCTG (nt 98-115, GenBank accession no. NM_002701). PCR reactions were prepared in duplicate and heated to 95degreesC for 10 minutes followed by 40 cycles of denaturation at 95degreesC for 10 seconds, annealing at 55degreesC for 5 seconds, and extension at 72degreesC for 20 seconds. All PCR reactions were performed in duplicate. Standard curves (cycle threshold values versus template concentration) were prepared for each target gene and for the endogenous reference (GAPDH) in each sample.
###end p 16
###begin title 17
Immunofluorescence Staining for Stem Cell Markers
###end title 17
###begin p 18
###xml 784 790 <span type="species:ncbi:9986">rabbit</span>
An avidin-biotin complex method was used for the immunofluorescence staining in the differentiated spheroid and neuronal-like cell. In brief, cells were plated onto poly-L-ornithine-coated glass coverslips and fixed with 4% paraformaldehyde for 15 to 20 minutes at room temperature, and then were washed twice (10 minutes each) with 1x PBS. Cells were permeabilized with 0.1% Triton X-100/PBS for 10 minutes at room temperature, and then twice (10 minutes each) with 1x PBS. The cells were then blocked with blocking solution for 30 minutes and were incubated with primary antibodies (Oct-4, Chemicon, Temecula, CA) for 1 hour at room temperature. We then washed the cells three times (10 minutes each) with 1x PBS. Immunoreactive signals were detected with a mixture of biotinylated rabbit antimouse IgG and Fluorsave (Calbiochem, San Diego, CA). Cells were further probed with fluorescein isothiocyanate (FITC)-tagged secondary antibodies. Fluorescence images were visualized with a fluorescence microscope. To quantitatively analyze the fluorescence intensity, we recorded images with an inverted fluorescence microscope equipped with a CCD camera. The percentage of signal fluorescence per photographed field was analyzed by image processing software (Image Pro-Plus, MediaCybernetics, Inc., Silver Spring, MD).
###end p 18
###begin title 19
FACS Analysis
###end title 19
###begin p 20
For cell surface marker identification, a single cell suspension of sixth- to eighth-passage cells from trypsinized spheres was stained with anti-CD133, CD117 (c-Kit), or ABCG2 and secondary fluorescein (FITC)-or phycoerythrin (PE)-coupled antibodies (Dako, Carpinteria). Cells were fixed with 2% paraformaldehyde and were analyzed with a BD FACSCalibur apparatus (Becton, Dickinson and Company, Franklin Lakes, NJ).
###end p 20
###begin title 21
Radiation Treatment for Cell Viability Analysis
###end title 21
###begin p 22
###xml 285 286 285 286 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
The gamma radiation (ionizing irradiation; IR) was delivered by a Theratronic cobalt unit T-1000 (Theratronic International, Inc., Ottawa, Canada) at a dose rate of 1.1Gy/min (SSD = 57.5cm). To evaluate the cell proliferation rate we seeded cells on 24-well plates at a density of 2x104 cells/well. Cells were seeded 24 hours after IR and then they were analyzed by methyle thiazol tetrazolium assay (MTT assay, Sigma-Aldrich, St. Louis, MN). The amount of MTT formazon product was determined by using a microplate reader and the absorbance was measured at 560 nm (SpectraMax 250, Molecular Devices, Sunnyvale, CA).
###end p 22
###begin title 23
Chemotherapeutic Agents
###end title 23
###begin p 24
Cisplatin, etoposide (VP16), and paclitaxel were obtained from Sigma-Aldrich and were dissolved in DMSO (Sigma-Aldrich) at 100 mM of stock solution.
###end p 24
###begin title 25
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In Vitro</italic>
In Vitro Cell Invasion Analysis and Soft Agar Colony Assay
###end title 25
###begin p 26
###xml 385 386 375 376 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 1034 1035 1020 1021 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 1252 1256 1232 1236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Yang1">[29]</xref>
The 24-well plate Transwell system with an 8-microm pore size polycarbonate filter membrane (Corning Costar, Corning, NY) was used. The filter membrane was coated with Matrigel (BD Biosciences, San Diego) diluted with serum-free medium and incubated overnight at 37degreesC. The cell suspensions were seeded to the upper compartment of the Transwell chamber at the cell density of 1x105 in 100 microl serum free medium. After 24 hours, the medium was removed and the filter membrane was fixed with 4% formalin for 1 hour. The opposite surface of the filter membrane facing the lower chamber was stained with Hoechst 33342 (Sigma-Aldrich) for 3 minutes and the migrated cells were then visualized under an inverted microscope. The protocol of soft agar colony assay is described as follows. Each well (35 mm) of a six-well culture dish was coated with 2 ml bottom agar mixture (DMEM, 10% (v/v) FCS, 0.6% (w/v) agar). After the bottom layer solidified, 2 ml top agar-medium mixture (DMEM, 10% (v/v) FCS, 0.3% (w/v) agar) containing 2x104 cells was added, and the dishes were incubated at 37degreesC for 4 weeks. Plates were stained with 0.5 ml of 0.005% crystal violet for 1 hour and then a dissecting microscope was used to count the number of colonies [29].
###end p 26
###begin title 27
Lentiviral-mediated RNAi
###end title 27
###begin p 28
###xml 242 306 242 306 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CCGGCCCTCACTTCACTGCACTGTACTCGAGTACAGTGC AGTGAAGTGAGGGTTTTT-3&#8242;</named-content>
###xml 317 322 <span type="species:ncbi:9606">human</span>
The pLVRNAi vector and pCDH-MCS1-EF1-copGFP vector were purchased from Biosettia Inc. (Biosettia, San Diego, CA). The method of cloning the double-stranded shRNA sequence is described in the manufacturer's protocol. The siRNA oligonucleotide 5'-CCGGCCCTCACTTCACTGCACTGTACTCGAGTACAGTGC AGTGAAGTGAGGGTTTTT-3' targeting human Oct-4 (NM_002701, nt 1035-1055) was synthesized and cloned into pLVRNAi to generate a lentiviral expression vector. The Oct-4 cDNA was amplified and purified by RT-PCR and cloned into a pCDH-MCS1-EF1-copGFP vector. Lentiviral production was done by transfection of 293T cells using Lipofectamine 2000 (LF2000, Invitrogen). Supernatants were collected 48 hours after transfection and then were filtered; the viral titers were then determined by FACS at 48 hours post-transduction. Subconfluent cells were infected with lentivirus at a multiplicity of infection of 5 in the presence of 8 ig/ml polybrene (Sigma-Aldrich).
###end p 28
###begin title 29
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In Vivo</italic>
In Vivo Analysis of Tumor Growth and Metastasis
###end title 29
###begin p 30
###xml 156 157 156 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 558 559 558 559 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 685 689 685 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Yang1">[29]</xref>
###xml 205 209 <span type="species:ncbi:10090">mice</span>
###xml 217 226 <span type="species:ncbi:10090">nude mice</span>
All procedures involving animals were in accordance with the institutional animal welfare guidelines of Taipei Veterans General Hospital. 1000, 3000, and 104 cells were injected into the tail vein of SCID mice and/or nude mice (BALB/c strain) each aged 8 weeks. In vivo GFP imaging was visualized and measured by an illuminating device (LT-9500 Illumatool TLS equipped with excitation illuminating source [470 nm] and filter plate [515 nm]). The tumor size was measured with calipers and the tumor volume was calculated according to the formula (LengthxWidth2)/2. The integrated optical density of green fluorescence intensity was captured and then analyzed by Image Pro-plus software [29].
###end p 30
###begin title 31
Statistical Analysis
###end title 31
###begin p 32
###xml 150 151 150 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 242 243 240 241 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 449 456 <span type="species:ncbi:9606">patient</span>
Statistical Package of Social Sciences software (version 13.0) (SPSS, Inc., Chicago, IL) was used for statistical analysis. The independent Student's t-test or ANOVA was used to compare the continuous variables between groups, whereas the chi2 test was applied for comparison of dichotomous variables. The Kaplan-Meier estimate was used for survival analysis, and the log-rank test was used to compare the cumulative survival durations in different patient groups. The level of statistical significance was set at 0.05 for all tests.
###end p 32
###begin title 33
Results
###end title 33
###begin title 34
Isolation and Characterization of Lung Cancer-derived CD133-positive Cells
###end title 34
###begin p 35
###xml 49 50 49 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 58 65 58 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g001">Fig. 1A</xref>
###xml 139 146 139 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002637-t001">Table 1</xref>
###xml 186 194 186 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002637.s001">Table S1</xref>
###xml 231 232 231 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 242 243 242 243 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 310 317 310 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g001">Fig. 1A</xref>
###xml 486 490 486 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Lee1">[30]</xref>
###xml 514 515 514 515 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 550 557 550 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002637-t001">Table 1</xref>
###xml 583 591 583 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002637.s001">Table S1</xref>
###xml 651 658 651 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g001">Fig. 1B</xref>
###xml 725 732 725 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g001">Fig. 1C</xref>
###xml 758 765 758 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g001">Fig. 1D</xref>
###xml 778 779 778 779 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 827 828 827 828 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 869 876 869 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 909 910 909 910 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 923 924 923 924 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 978 979 978 979 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 1046 1047 1046 1047 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 1056 1057 1056 1057 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1107 1108 1107 1108 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1259 1266 1259 1266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002637-t001">Table 1</xref>
###xml 1271 1279 1271 1279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002637.s001">Table S1</xref>
###xml 129 137 <span type="species:ncbi:9606">patients</span>
###xml 540 548 <span type="species:ncbi:9606">patients</span>
###xml 1014 1018 <span type="species:ncbi:10090">mice</span>
###xml 1145 1153 <span type="species:ncbi:9606">patients</span>
###xml 1197 1201 <span type="species:ncbi:10090">mice</span>
Using the magnetic bead method, we isolated CD133+ cells (Fig. 1A) from tissue samples of ten non-small cell lung cancer (NSCLC) patients (Table 1) and five lung cancer (LC) cell lines (Table S1). The high percentage (97%) of CD133+ (LC-CD133+) subset was isolated in the LC tissues and parental LC cell line (Fig. 1A). It has been reported that cancer stem-like cells can be cultured in suspension to generate floating spheroid-like bodies (SB) under serum-free medium with bFGF & EGF [30]. We found that LC-CD133+ isolated from these ten patients (Table 1) and five LC cell lines (Table S1) can form SB in DF-12 serum-free medium with bFGF and EGF (Fig. 1B; No.1 [PLC] and No.2 [LLC]). Furthermore, the ability to form SB (Fig. 1C) and proliferation rate (Fig. 1D) in LC-CD133+ were significantly higher than that in LC-CD133- (p<0.05). In addition, to determine the in vivo tumorigenic activity of LC-CD133+ and LC-CD133-, we injected respective amounts of 1000, 3000, and 104 cells into the tail veins of SCID mice. The results showed that 104 LC-CD133- did not induce tumor formation but 3,000 LC-CD133+ from the lung cancer tissues of ten patients and five LC cell lines in xenotransplanted mice can all generate visible tumors 4 weeks after injection (Table 1 and Table S1).
###end p 35
###begin title 36
###xml 59 60 59 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 70 71 70 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Isolation and characterization of lung cancer-derived CD133+ (LC-CD133+).
###end title 36
###begin p 37
###xml 49 50 49 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 162 163 162 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 208 209 208 209 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 230 231 230 231 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 376 377 376 377 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 390 391 390 391 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 466 467 466 467 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 480 481 480 481 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 80 88 <span type="species:ncbi:9606">patients</span>
###xml 180 187 <span type="species:ncbi:9606">patient</span>
(A) Using a magnetic bead method, we sorted CD133+ cells from tissue samples of patients with lung cancer (LC), and characterized them by FACS assay. (B) LC-CD133+ sorted from two patient with No.1 (PLC-CD133+) and No.2 (LLC-CD133+) were cultured in bFGF and EGF with DMEM serum-free medium. (C) Evaluation of the formation abilities of spheroid-like bodies (SB) from LC-CD133+ and LC-CD133- under serum-free medium with bFGF & EGF. (D) The growth curves of LC-CD133+ and LC-CD133- were measured by hemocytometer. Bar: 100 microm. Data shown here are the mean+/-SD of three experiments.
###end p 37
###begin title 38
###xml 59 60 59 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 60 68 60 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In Vitro</italic>
Increased ABCG2 Expression and Invasive Ability of LC-CD133+In Vitro
###end title 38
###begin p 39
###xml 37 38 37 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 134 143 134 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g002">Figure 2A</xref>
###xml 178 179 178 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 280 281 280 281 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 330 331 330 331 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 366 373 366 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g002">Fig. 2B</xref>
###xml 441 442 441 442 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 456 464 456 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 563 564 563 564 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 574 575 574 575 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 706 707 706 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 715 722 715 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g002">Fig. 2C</xref>
###xml 774 775 774 775 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 851 852 851 852 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 876 877 876 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 885 892 885 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g002">Fig. 2D</xref>
###xml 595 603 <span type="species:ncbi:9606">Patients</span>
###xml 866 874 <span type="species:ncbi:9606">patients</span>
To characterize our isolated LC-CD133+, FACS analysis was used to detect the expression profile of cells surface markers. As shown in Figure 2A, the majority of isolated LC-CD133+ were stained with higher expression levels of CD133, CD117 (c-Kit), and ABCG2 compared with LC-CD133-. This result demonstrated that isolated LC-CD133+ were almost ABCG2-positive cells (Fig. 2B). To further evaluate the enhancement of tumorigenicity of LC-CD133+, we examined in vitro Matrigel-combined Transwell invasion and soft agar colony formation assays. Compared with LC-CD133-, LC-CD133+ derived from NSCLC Patients No.1 (PLC) and No. 2 (LLC) showed higher invasion activity through Matrigel Transwell invasion assay (p<0.001; Fig. 2C). Similarly, the foci formation ability of LC-CD133+ from PLC (No.1) and LLC (No.2) was enhanced when compared with the LC-CD133- of those two patients (p<0.001; Fig. 2D).
###end p 39
###begin title 40
###xml 63 64 63 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 77 78 77 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 78 86 78 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Detection of surface markers and the tumorigenicity in LC-CD133+ and LC-CD133-in vitro.
###end title 40
###begin p 41
###xml 108 109 108 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 122 123 122 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 235 236 235 236 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 288 289 288 289 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 292 293 292 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(A) and (B) The expression levels of CD133, CD117 (c-Kit), and ABCG2 were analyzed by FACS assay in LC-CD133+ and LC-CD133-. The capabilities of (C) the migration/invasion and (D) the tumor foci (soft agar colony) formation in LC-CD133+ were significantly increased compared with LC-CD133- (*p<0.001). Data shown here are the mean+/-SD of three experiments.
###end p 41
###begin title 42
###xml 10 17 10 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In Vivo</italic>
###xml 73 74 73 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Increased In Vivo Tumor-restoration and Proliferative Ability in LC-CD133+
###end title 42
###begin p 43
###xml 25 32 25 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 88 89 88 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 102 103 102 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 149 156 149 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g003">Fig. 3A</xref>
###xml 178 179 178 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 341 342 341 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 359 374 359 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g003">Figs. 3A4 &amp; 3A7</xref>
###xml 399 400 399 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 408 416 408 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g003">Fig. 3A1</xref>
###xml 452 453 452 453 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 517 540 517 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g003">Figs. 3A5, 3A6, and 3A8</xref>
###xml 699 700 699 700 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 721 729 721 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g003">Fig. 3A9</xref>
###xml 830 831 830 831 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 852 867 852 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g003">Figs. 3A2 &amp; 3A3</xref>
###xml 898 905 898 905 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 929 930 929 930 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 939 940 939 940 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 950 951 950 951 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 960 961 960 961 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 977 978 977 978 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1082 1083 1082 1083 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 1092 1093 1092 1093 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1135 1142 1135 1142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002637-t001">Table 1</xref>
###xml 1188 1189 1188 1189 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1198 1199 1198 1199 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1214 1215 1214 1215 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1243 1250 1243 1250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g003">Fig. 3B</xref>
###xml 1268 1269 1268 1269 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 1278 1279 1278 1279 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1501 1508 1501 1508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g003">Fig. 3C</xref>
###xml 1545 1546 1545 1546 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1643 1650 1643 1650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g003">Fig. 3C</xref>
###xml 1693 1694 1693 1694 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1752 1760 1752 1760 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1765 1772 1765 1772 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 228 232 <span type="species:ncbi:10090">mice</span>
###xml 715 719 <span type="species:ncbi:10090">mice</span>
###xml 846 850 <span type="species:ncbi:10090">mice</span>
###xml 1012 1019 <span type="species:ncbi:9606">patient</span>
###xml 1106 1114 <span type="species:ncbi:9606">Patients</span>
###xml 1375 1379 <span type="species:ncbi:10090">mice</span>
###xml 1637 1641 <span type="species:ncbi:10090">mice</span>
We further evaluated the in vivo tumor-restoration and proliferative ability of LC-CD133+ and LC-CD133- by xenotransplanted tumorigenicity analysis (Fig. 3A). Four weeks after 104 cells were injected into the tail veins of SCID mice, a significant increase in the multiple nodules of tumor formation on lung surface was noted in the LC-CD133+-injected group (Figs. 3A4 & 3A7) but not in the LC-CD133- group (Fig. 3A1). Diffuse infiltrations of LC-CD133+ from the lung parenchyma to the alveolar cavity were observed (Figs. 3A5, 3A6, and 3A8). The histological examination demonstrated that the prominent neovascularization and thrombus formation were detected in the pulmonary parenchyma of LC-CD133+-injected SCID mice (Fig. 3A9). In contrast, no significant tumor foci or neovascular formation was found in the lungs of LC-CD133--injected SCID mice (Figs. 3A2 & 3A3). We further investigated the in vivo tumor growth rate in 104 LC-CD133+ cells, 106 LC-CD133- cells, and 5x106 parent tumor cells from the same patient. The finding demonstrated that the tumor growth rate of the 104 LC-CD133+ group (from Patients No. 1, 2, 4, and 7; Table 1) was significantly higher than that of the 106 LC-CD133- group and 5x106 parental tumor cell group (Fig. 3B). Furthermore, 104 LC-CD133+ isolated from secondary tumors can further generate new (second) tumors from transplanted SCID mice. Results of flow cytometry showed that a high percentage (60%) of CD133-positive cells was detected in the second tumor (Fig. 3C). In addition, one thousand LC-CD133+ isolated from the second tumor can also generate a new (third) tumor in transplanted SCID mice (Fig. 3C). To sum, our data indicated that LC-CD133+ present self-renewing and repopulation capabilities both in vitro and in vivo.
###end p 43
###begin title 44
###xml 44 45 44 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 58 59 58 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 59 66 59 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Evaluation of the tumorigenicity of LC-CD133+ and LC-CD133-in vivo.
###end title 44
###begin p 45
###xml 9 15 9 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n vivo</italic>
###xml 42 43 42 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 56 57 56 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 157 158 157 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 217 218 217 218 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 259 260 259 260 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 326 333 322 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 383 384 379 380 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 393 394 389 390 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 398 399 394 395 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 408 409 404 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 418 419 414 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 575 576 571 572 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 701 702 697 698 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 80 84 <span type="species:ncbi:10090">mice</span>
###xml 443 450 <span type="species:ncbi:9606">patient</span>
###xml 610 614 <span type="species:ncbi:10090">mice</span>
(A) The in vivo tumorigenicity of LC-CD133+ and LC-CD133- in tail vein-injected mice was analyzed by macroscopic and histological examination. A1-3: LC-CD133-; arrows: normal alveolar structure of lung. A4-6: LC-CD133+; arrows: tumor formation. A7-9: LC-CD133+; arrows: neovascularity and thrombosis. Bar: 200 microm. (B) The in vivo tumor-restoration and proliferative ability of 104 LC-CD133+, 105 LC-CD133- and 5x105 total tumor cells from patient No. 1, 2, 4, and 7 were examined by xenotransplanted tumorigenicity analysis. (C) The tumor repopulation ability of LC-CD133+ was studied in transplanted SCID mice. The expression levels of CD133 were determined by FACS analysis from primary LC-CD133+, second tumor, and third tumor. Data shown here are the mean+/-SD of three experiments.
###end p 45
###begin title 46
###xml 52 53 52 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Enhanced Chemo- and Radiation-resistance in LC-CD133+
###end title 46
###begin p 47
###xml 73 74 73 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 87 88 87 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 230 232 230 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;,</sup>
###xml 241 242 241 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 315 316 315 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 323 330 323 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g004">Fig. 4A</xref>
###xml 482 483 482 483 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 496 497 496 497 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 511 518 511 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g003">Fig. 3B</xref>
###xml 580 581 580 581 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 630 631 630 631 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 633 634 633 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 676 677 676 677 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 728 729 728 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 736 743 736 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g004">Fig. 4B</xref>
###xml 834 835 834 835 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 984 985 976 977 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 999 1008 991 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g003">Figure 3C</xref>
###xml 1078 1079 1070 1071 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1180 1181 1172 1173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1319 1320 1311 1312 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1322 1323 1314 1315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1330 1337 1322 1329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g004">Fig. 4C</xref>
###xml 1375 1376 1367 1368 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
We evaluated the multidrug (chemotherapy)-resistant abilities of LC-CD133+ and LC-CD133-. We further tested four common chemotherapeutic agents including cisplatin, VP16 (etoposide), doxorubicin, paclitaxel. Compared with LC-CD133-, LC-CD133+ are significantly resistant to the four tested chemotherapeutic agents (p<0.01; Fig. 4A). To further determine the radiation effect on the rate of tumor growth, we used an ionizing radiation (IR) dose from 0 to 10 Gy to treat both LC-CD133+ and LC-CD133-. As shown in Fig. 3B, after IR treatment, the survival rate and number of LC-CD133+ were significantly higher than those of LC-CD133- (p<0.01). We further found that the LC-CD133+ cells possess a higher degree of radioresistance (p<0.01; Fig. 4B). Moreover, we investigated the combined treatment effect of radiochemotherapy in LC-CD133+. Experiments were conducted with cisplatin (10 microM) alone, VP-16 (10 microM) alone, or combined cisplatin and VP-16 on IR (2 Gy)-treated LC-CD133+. As shown in Figure 3C, the data revealed that the cell survival rate in IR-treated LC-CD133+ was not significantly decreased by the IR treatment combined with cisplatin, with or without VP-16 (p>0.05). On the contrary, cell survival significantly declined after chemotherapy with cisplatin combined with VP-16 in IR-treated LC-CD133- (p<0.01; Fig. 4C). These results suggest that LC-CD133+ may play a vital role in the tumor's ability to resist radiation and chemotherapies.
###end p 47
###begin title 48
###xml 48 49 48 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 62 63 62 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
Chemodrugs and radiation sensitivity of LC-CD133+ and LC-CD133-.
###end title 48
###begin p 49
###xml 24 25 24 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 38 39 38 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 387 388 387 388 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 401 402 401 402 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 405 406 405 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 421 422 421 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 445 446 445 446 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 514 515 514 515 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 528 529 528 529 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 718 719 710 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(A) Both 10,000 LC-CD133+ and LC-CD133- were plated in a 96-well plate and treated with various concentrations of cisplatin, VP-16, doxorubicin, and paclitaxel for 24 hours in 10% FBS/DMEM/F-12 medium. The survival rate was determined by MTT assay. (B) To determine the radiation effect on the tumor growth rate, an ionizing radiation (IR) dose from 0 to 10 Gy was used to treat LC-CD133+ and LC-CD133-. *p<0.01: LC-CD133+ compared with LC-CD133-. (C) The combined treatment effect of radiochemotherapy in LC-CD133+ and LC-CD133- were further evaluated. The four protocols-radiation (2 Gy) only, radiation with cisplatin (10 microM), radiation with VP-16 (10 microM), and radiation with paclitaxel (10 nM)-were used. *p<0.01. Data shown here are the mean+/-SD of three experiments.
###end p 49
###begin title 50
###xml 36 37 36 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Role of Oct-4 Expression in LC-CD133+
###end title 50
###begin p 51
###xml 106 107 106 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 160 161 160 161 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 329 330 329 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 428 429 428 429 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 481 496 481 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g005">Figs. 5A and 5B</xref>
###xml 622 623 622 623 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 718 719 718 719 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 788 789 788 789 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 880 881 880 881 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 889 896 889 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g005">Fig. 5C</xref>
###xml 960 961 960 961 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1054 1061 1054 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g005">Fig. 5C</xref>
###xml 1174 1175 1174 1175 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1177 1184 1177 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g005">Fig. 5C</xref>
###xml 1205 1206 1205 1206 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1275 1282 1275 1282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g005">Fig. 5D</xref>
###xml 1394 1395 1394 1395 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1462 1469 1462 1469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g005">Fig. 5D</xref>
###xml 1576 1577 1576 1577 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1609 1610 1609 1610 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1651 1652 1651 1652 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1692 1693 1692 1693 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1701 1708 1701 1708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g005">Fig. 5E</xref>
###xml 1851 1852 1851 1852 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 332 340 <span type="species:ncbi:9606">Patients</span>
Microarray results suggested that the expression level of Oct-4 self-renewal and stemness gene in LC-CD133+ was significantly up-regulated than that in LC-CD133-. To validate this finding, we examined expression of Oct-4 both transcriptionally and translationally. The amounts of Oct-4 transcript and protein of isolated LC-CD133+ (Patients No.1 [PLC] and No.2 [LLC]) were significantly increased compared with those of LC-CD133- by real-time RT-PCR and western blotting analysis (Figs. 5A and 5B). To investigate whether Oct-4 expression plays a role in maintaining self-renewal or cancer stem-like properties in LC-CD133+, we used the siRNA method with lentiviral vector for knockdown of Oct-4 expression in LC-CD133+. We found it important that the treatment of Oct-4 siRNA in LC-CD133+ can significantly interfere with the capabilities of spheroid-like bodies (SB) formation (p<0.001; Fig. 5C). After 7 days of the Oct-4 siRNA treatment, the SB of LC-CD133+ could not maintain floating spheres but differentiated into attached epithelial-like cells (Fig. 5C). In contrast, the treatment of scramble control siRNA did not influence the SB formation capability in LC-CD133+ (Fig. 5C). The SB of LC-CD133+ endogenously expressed strong positive signals for Oct-4 and CD133 (Fig. 5D). Furthermore, the immunofluorescent results demonstrated that both the CD133 and Oct-4 expressions in LC-CD133+ were significantly blocked after 7 days of Oct-4 siRNA treatment (Fig. 5D). FASC assay confirmed that the amount of CD133 was dramatically decreased in Oct-4 siRNA-treated LC-CD133+ and the percentages of LC-CD133- were significantly increased in LC-CD133+ after 7 days of Oct-4 siRNA treatment (p<0.001; Fig. 5E). These data suggested that Oct-4 may maintain the properties of primitive stem cells and inhibit the tendency for differentiation in LC-CD133+.
###end p 51
###begin title 52
###xml 62 63 62 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Up-regulated expressions of Oct-4 mRNA and protein in LC-CD133+.
###end title 52
###begin p 53
###xml 57 58 57 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 119 120 119 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 225 226 225 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 320 321 320 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 370 371 370 371 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 449 450 449 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 713 714 709 710 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 820 821 812 813 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 882 883 874 875 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 900 901 892 893 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(A) The amounts of Oct-4 transcripts of isolated LC-CD133+ were significantly increased compared with those of LC-CD133- by real-time RT-PCR analyses. (B) Western blott data showed that the protein levels of Oct-4 in LC-CD133+ isolated from PLC and LLC were also significantly upregulated compared with those of LC-CD133-. (C) The protein expression of Oct-4 in LC-CD133+ were effectively blocked by Oct-4 siRNA. Treatment of Oct-4 siRNA in LC-CD133+ can impede the capabilities of SB formation and further facilitate SB to differentiate into attached epithelial-like cells. Bar: 100 microm. (D) By using immunofluorescent staining, we showed that the protein expression levels of both Oct-4 and CD133 in LC-CD133+ were significantly diminished after Oct-4 siRNA treatment. Bar: 30 microm. (E) The proportion of LC-CD133- were significantly increased in Oct-4 siRNA-treated LC-CD133+ by FACS assay. *p<0.001. Data shown here are the mean+/-SD of three experiments.
###end p 53
###begin title 54
###xml 77 78 77 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Enhanced Chemoradiotherapeutic Sensitivity and Apoptotic Activity in LC-CD133+ Treated by Oct-4 siRNA
###end title 54
###begin p 55
###xml 66 67 66 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 67 75 67 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 183 191 183 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 243 244 243 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 331 332 331 332 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 345 346 345 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 385 386 385 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 394 401 394 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g006">Fig. 6A</xref>
###xml 475 476 475 476 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 579 580 579 580 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 592 593 592 593 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 621 628 621 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g006">Fig. 6B</xref>
###xml 630 631 630 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 706 713 706 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g006">Fig. 6C</xref>
###xml 730 737 730 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g006">Fig. 6D</xref>
###xml 799 800 799 800 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 940 941 940 941 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 943 950 943 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g006">Fig. 6B</xref>
###xml 1087 1088 1087 1088 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1157 1164 1157 1164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g006">Fig. 6D</xref>
###xml 1226 1227 1226 1227 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1397 1398 1397 1398 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
To further study the role of Oct-4 in tumor malignancy of LC-CD133+in vitro, the migration/invasive and soft agar colony assay were used. The results showed that the abilities of the in vitro migratory invasion and colony formation in LC-CD133+ treated by Oct-4 siRNA were significantly decreased compared with non-treated LC-CD133+, or LC-CD133+ treated with scramble-siRNA (control; p<0.001; Fig. 6A). Furthermore, the treatment effect of chemoradiotherapy for the LC-CD133+ group can be significantly improved by the treatment of Oct-4 siRNA compared with non-treated LC-CD133+ or LC-CD133+ treated by scramble-siRNA (Fig. 6B; p<0.001). In addition, we found that the apoptotic activities of annexin V (Fig. 6C) and caspase 3 (Fig. 6D; upper part) were quickly and effectively induced in LC-CD133+ treated by Oct-4 siRNA after 72 hours. In accordance with the result of cell survival and treatment effects in Oct-4 siRNA-treated LC-CD133+ (Fig. 6B), the western blot data further demonstrated that the amounts of activated (cleaved) form of PARP were consistently elevated in LC-CD133+ treated by Oct-4 siRNA with IR alone or combined with chemotherapy (Fig. 6D; lower part). Thus, knockdown of Oct-4 expression in LC-CD133+ can effectively enhance chemoradiosensitivities and apoptotic activities in response to IR and chemotherapy, suggesting that Oct-4 could be a key factor enables LC-CD133+ to resist radiochemotherapeutic stress.
###end p 55
###begin title 56
###xml 108 109 108 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Evaluation of the chemoradiosensitivity and apoptotic activity in the knockdown Oct-4 expression of LC-CD133+.
###end title 56
###begin p 57
###xml 63 64 63 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 162 163 162 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 175 176 175 176 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 215 216 215 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 315 316 315 316 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 366 367 366 367 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 707 708 707 708 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 847 848 847 848 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 925 926 925 926 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 941 942 941 942 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 975 978 975 978 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 987 988 987 988 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1013 1014 1013 1014 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1029 1030 1029 1030 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1070 1073 1070 1073 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 1082 1083 1082 1083 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
(A) Migratory invasion ability and colony formation of LC-CD133+ treated by Oct-4 siRNA was significantly decreased compared with non-Oct-4 siRNA-treated LC-CD133+ or LC-CD133+ treated with scramble-siRNA (control; p<0.001). (B) The combined treatment effect of radiochemotherapy in non-Oct-4 siRNA-treated LC-CD133+, scramble-siRNA, and Oct-4 siRNA-treated LC-CD133+ were further evaluated. Three groups of cells were exposed to IR (2 Gy) only or radiation plus cisplatin. The cell survival rate was determined by MTT assay. After 72 hours of Oct-4 siRNA treatment, (C) the percentage of Annexin V-positive cells and (D) the activities of caspase 3 (detected by ELISA assay) in Oct-4 siRNA-treated LC-CD133+ were significantly increased. (D) The western blot data further showed that PARP was significantly induced in Oct-4 siRNA-treated LC-CD133+ when exposed to IR alone, cisplatin alone, or IR combined with cisplatin. (*p<0.05: LC-CD133+ with Oct-4 siRNA plus cisplatin vs. LC-CD133+ with Oct-4 siRNA only. #p<0.05: LC-CD133+ with Oct-4 siRNA plus cisplatin and IR vs. LC-CD133+ with Oct-4 siRNA plus IR). Bar: 50 microm. Data shown here are the mean+/-SD of three experiments.
###end p 57
###begin title 58
###xml 14 21 14 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In Vivo</italic>
###xml 75 76 75 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Inhibition of In Vivo Tumorgeneic Potential in Oct-4 siRNA-treated LC-CD133+
###end title 58
###begin p 59
###xml 89 90 89 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 100 101 100 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 200 207 200 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 309 310 309 310 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 319 320 319 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 486 487 486 487 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 562 563 562 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 570 577 570 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g007">Fig. 7A</xref>
###xml 661 662 661 662 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 708 709 708 709 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 718 719 718 719 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 805 812 805 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 918 919 918 919 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 978 979 978 979 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1016 1017 1016 1017 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1024 1031 1024 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g007">Fig. 7B</xref>
###xml 1115 1116 1115 1116 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1116 1123 1116 1123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1269 1276 1269 1276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g007">Fig. 7C</xref>
###xml 1379 1380 1379 1380 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1467 1474 1467 1474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g007">Fig. 7C</xref>
###xml 1554 1555 1554 1555 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1630 1631 1630 1631 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1638 1645 1638 1645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g007">Fig. 7C</xref>
###xml 1764 1765 1764 1765 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1851 1852 1851 1852 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1859 1866 1859 1866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g007">Fig. 7D</xref>
###xml 1874 1881 1874 1881 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1966 1967 1966 1967 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 362 371 <span type="species:ncbi:10090">nude mice</span>
###xml 784 788 <span type="species:ncbi:10090">mice</span>
###xml 1218 1222 <span type="species:ncbi:10090">mice</span>
###xml 1395 1399 <span type="species:ncbi:10090">mice</span>
To investigate the treatment effects of chemoradiotherapy on Oct-4 siRNA-treated LC-CD133+, LC-CD133+ was first transfected by lentivector combined with green fluorescent protein gene (GFP), and then in vivo GFP imaging and histological study were used to monitor the tumor-growth effect. We first injected 104 LC-CD133+-GFP cells into the subcutaneous sites of nude mice with different treatment protocols. The tumor volumes were significantly decreased in Oct-4 siRNA-treated LC-CD133+ when exposed to IR alone, cisplatin alone, or IR combined with cisplatin (p<0.01; Fig. 7A). To further evaluate the capabilities of tumor invasion and metastasis of LC-CD133+ treated by different regimens, we injected 104 LC-CD133+-GFP cells from each treatment groups into the tail vein of SCID mice. The results of in vivo GFP imaging showed that the tumor foci of lung and metastatic lesions in the Oct-4-siRNA-treated LC-CD133+ groups were significantly lower than those of the LC-CD133+ without Oct-4-siRNA-treated groups (p<0.01; Fig. 7B). In addition, to investigate the treatment effects of Oct-4 expression in LC-CD133+in vivo, we injected the seven groups with different regimens individually into the tail vein of SCID mice for xenotransplanted tumorigenicity analysis (Fig. 7C). Immunohistochemistry (IHC) showed that the expression levels of Oct-4 in the lung tumors of LC-CD133+-injected SCID mice were highly expressed in comparison with the other treated-groups (Fig. 7C). Oct-4-IHC levels were significantly decreased in Oct-4 siRNA-treated LC-CD133+ when exposed to IR alone, cisplatin alone, or IR combined with cisplatin (p<0.01; Fig. 7C). Moreover, using combined chemoradiotherapy with the treatment of Oct-4 siRNA, the mean survival rate of the LC-CD133+ group was significantly prolonged compared with the control or other treated groups (p<0.05; Fig. 7D). This in vivo study also confirmed that the treatment effect of chemoradiotherapy for the LC-CD133+ group can be improved by the treatment of Oct-4 siRNA.
###end p 59
###begin title 60
###xml 66 67 66 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Inhibition of tumorgeneic activity in Oct-4 siRNA-treated LC-CD133+ with chemoradiotherapy.
###end title 60
###begin p 61
###xml 8 9 8 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 17 18 17 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 239 240 239 240 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 354 355 354 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 370 371 370 371 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 397 400 397 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 409 410 409 410 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 413 414 413 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 429 430 429 430 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 471 474 471 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 483 484 483 484 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 516 517 516 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 532 533 532 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 567 570 567 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 579 580 579 580 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 605 606 605 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 621 622 621 622 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 670 673 670 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 682 683 682 683 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 719 726 719 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 761 762 761 762 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 776 777 776 777 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 916 917 916 917 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1189 1190 1185 1186 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1200 1201 1196 1197 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1234 1235 1230 1231 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1285 1286 1281 1282 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 101 110 <span type="species:ncbi:10090">nude mice</span>
###xml 792 796 <span type="species:ncbi:10090">mice</span>
###xml 932 936 <span type="species:ncbi:10090">mice</span>
###xml 1164 1168 <span type="species:ncbi:10090">mice</span>
###xml 1376 1380 <span type="species:ncbi:10090">mice</span>
LC-CD133+-GFP (104) cells of different treatment groups were injected into the subcutaneous sites of nude mice. (A) The tumor volume and (B) The number of pulmonary tumor nodules were significantly decreased in Oct-4 siRNA-treated LC-CD133+ when exposed to IR alone, cisplatin alone, or IR combined with cisplatin. Cis: cisplatin; Oct-4i: Oct-4 siRNA. (#p<0.01: LC-CD133+ treated with Oct-4 siRNA vs. LC-CD133+. *p<0.01: LC-CD133+ treated with Oct-4 siRNA plus cisplatin vs. LC-CD133+ treated with cisplatin only. **p<0.01: LC-CD133+ treated with Oct-4 siRNA plus IR vs. LC-CD133+ treated with IR only. ##p<0.01: LC-CD133+ treated with Oct-4 siRNA plus cisplatin and IR vs. LC-CD133+ with Oct-4 siRNA plus IR). (C) The in vivo tumorgeneic activities of LC-CD133+- and LC-CD133--injected SCID mice were evaluated by histological review (left upper part). The expression levels of Oct-4 in the lung lesions of LC-CD133+-injected SCID mice with the different treatment protocol were studied by immunohistochemistry (IHC). The black arrows indicate the positive signals for Oct-4 expression in the tumors detected by IHC. Bar: 50 microm. (D) Survival analysis of SCID mice injected by LC-CD133+, LC-CD133+ treated with cisplatin, LC-CD133+ treated with IR, and Oct-4 siRNA-treated LC-CD133+ groups (IR alone, cisplatin alone, or IR combined with cisplatin). Each group tested six mice (n = 6). Data shown here are the mean+/-SD of three experiments.
###end p 61
###begin title 62
Discussion
###end title 62
###begin p 63
###xml 149 153 149 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Boiani1">[24]</xref>
###xml 154 158 154 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Lamb1">[26]</xref>
###xml 325 329 325 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Okita1">[31]</xref>
###xml 330 334 330 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Yu1">[33]</xref>
###xml 424 428 424 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Ling1">[34]</xref>
###xml 580 584 580 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Jin1">[35]</xref>
###xml 585 589 585 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Gidekel1">[38]</xref>
###xml 804 808 804 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Ponti1">[39]</xref>
###xml 876 877 876 877 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 944 945 944 945 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1000 1008 1000 1008 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1013 1020 1013 1020 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1022 1029 1022 1029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g001">Figs. 1</xref>
###xml 1031 1032 1031 1032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g002">2</xref>
###xml 1038 1039 1038 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g003">3</xref>
###xml 1050 1051 1050 1051 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1118 1124 1118 1124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g004">Fig. 4</xref>
###xml 1236 1237 1236 1237 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1239 1245 1239 1245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g005">Fig. 5</xref>
###xml 1368 1372 1368 1372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Okita1">[31]</xref>
###xml 1373 1377 1373 1377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Yu1">[33]</xref>
###xml 1470 1471 1470 1471 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1565 1566 1565 1566 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1598 1599 1598 1599 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1630 1631 1630 1631 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1633 1639 1633 1639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g005">Fig. 5</xref>
###xml 1655 1662 1655 1662 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1738 1739 1738 1739 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1892 1893 1892 1893 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1975 1981 1975 1981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g007">Fig. 7</xref>
###xml 2118 2129 2118 2129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002637.s002">Figs. S1A&#8211;C</xref>
###xml 2296 2297 2296 2297 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 370 375 <span type="species:ncbi:10090">mouse</span>
###xml 489 494 <span type="species:ncbi:9606">human</span>
###xml 641 646 <span type="species:ncbi:9606">human</span>
###xml 1754 1758 <span type="species:ncbi:10090">mice</span>
###xml 1903 1907 <span type="species:ncbi:10090">mice</span>
Self-renewal and pluripotency are the central features in the definition of embryonic stem cells (ESC), and Oct-4 is a key regulator in this process [24]-[26]. Oct-4 has been suggested as one of four major factors that render the reprogramming capability of adult cells into germline-competent-induced pluripotent stem cells [31]-[33]. Previous studies also showed that mouse pulmonary stem cells endogenously express Oct-4 [34]. Recently, Oct-4 transcript can be consistently detected in human embryonal carcinomas, testicular germ cell tumors, seminomas, and bladder carcinomas [35]-[38]. The expression of Oct-4 has further been shown in human breast cancer stem-like cells, suggesting that its expression may be implicated in self-renewal and tumorigenesis via activating its downstream target genes [39]. Herein we reported the isolation of CD133-positive cells (LC-CD133+) from clinical tissue samples and lung cancer cell lines. LC-CD133+ showed strong proliferative and invasive capabilities in vitro and in vivo (Figs. 1, 2, and 3). LC-CD133+ also displayed significant resistance to chemotherapeutic agents (Fig. 4). We also demonstrated that Oct-4 expression was transcriptionally and translationally up-regulated in LC-CD133+ (Fig. 5). Indeed, Oct-4 functions as a master switch during differentiation by regulating the pluripotent potential in stem cells [31]-[33]. Using the siRNA method with lentiviral vector for knockdown of Oct-4 expression in LC-CD133+, our data showed that the treatment of Oct-4 siRNA can block the sphere formation of LC-CD133+ and further facilitate LC-CD133+ to differentiate into LC-CD133- (Fig. 5). Furthermore, in vivo animal studies demonstrated the IHC of Oct-4 in the lung tumors of LC-CD133+-injected SCID mice were prominently up-regulated, and the total lung tumor volume as well as Oct-4 IHC levels can be significantly decreased in LC-CD133+-injected mice by the treatment of Oct-4 siRNA with or without chemoradiotherapy (Fig. 7). In addition, we showed that increased incidence of Oct-4 expression correlated positively with the advanced stage of 78 lung cancers (Figs. S1A-C). To our knowledge, this is the first study to show that Oct-4 expression plays a crucial role in maintaining self-renewal and cancer stem-like properties in LC-CD133+.
###end p 63
###begin p 64
###xml 149 152 149 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Jordan1">[6]</xref>
###xml 364 367 364 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Jordan1">[6]</xref>
###xml 369 373 369 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Clarke1">[40]</xref>
###xml 375 379 375 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Elkind1">[41]</xref>
###xml 423 424 423 424 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 528 529 528 529 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 531 532 531 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 540 546 540 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g004">Fig. 4</xref>
###xml 632 633 632 633 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 635 641 635 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g004">Fig. 4</xref>
###xml 752 753 752 753 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 755 762 755 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g004">Fig. 4D</xref>
###xml 832 833 832 833 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 924 925 924 925 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1017 1018 1017 1018 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1018 1026 1018 1026 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1031 1038 1031 1038 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1040 1047 1040 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g006">Figs. 6</xref>
###xml 1052 1053 1052 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g007">7</xref>
###xml 1104 1105 1104 1105 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1204 1210 1204 1210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g007">Fig. 7</xref>
###xml 1381 1385 1381 1385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Guo1">[42]</xref>
###xml 1543 1544 1543 1544 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1612 1618 1612 1618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g006">Fig. 6</xref>
###xml 1638 1645 1638 1645 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1734 1735 1734 1735 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1737 1744 1737 1744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g007">Fig. 7C</xref>
###xml 1791 1798 1791 1798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002637.s002">Fig. S1</xref>
###xml 1974 1975 1974 1975 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1753 1761 <span type="species:ncbi:9606">patients</span>
###xml 2037 2045 <span type="species:ncbi:9606">patients</span>
The property of resistance to chemotherapy and irradiation treatment is the major clinical criterion to characterize "cancer stem-like cells (CSCs)" [6]. The existence of cancer stem-like cells may explain why conventional anti-cancer therapies are able only to suppress or shrink a tumor but often cannot completely eradicate it, resulting in eventual recurrence [6], [40], [41]. Consistent with these hypotheses, LC-CD133+ were significantly resistant to cisplatin, VP16 (eptoposide), doxorubicin, and paclitaxel than LC-CD133- (p<0.001; Fig. 4). Even IR alone or a single chemodrug can effectively inhibit cell growth of LC-CD133- (Fig. 4); however, IR treatment combined with cisplatin and VP-16 still failed to cause cell death in treated LC-CD133+ (Fig. 4D). To overcome resistance to radiotherapy and chemotherapy in LC-CD133+, treatment of Oct-4 siRNA was used and results showed that the knockdown Oct-4 in LC-CD133+ can significantly improve the anti-cancer effect in single- or combination-treated LC-CD133+in vitro and in vivo (Figs. 6 and 7). Moreover, the mean survival rate of the LC-CD133+ group can be significantly prolonged after the treatment of Oct-4 siRNA with IR and chemotherapy (Fig. 7). Recently, Oct-4 has been suggested to be a protector for survival of ES cells from apoptosis induced by etoposide, UV, or heat shock through the Stat3/Survivin pathway [42]. Consistent with this important finding, our results suggest that knockdown of Oct-4 expression can effectively enhance the chemoradiosensitivity of LC-CD133+ through activating the apoptotic activities of caspase 3 and PARP (Fig. 6). Importantly, our in vivo animal study and clinical data provide the evidence that the amount of Oct-4 in LC-CD133+ (Fig. 7C) and in patients with high-grade lung cancer (Fig. S1) is positively correlated with the degree of resistance to chemoradiation therapy. Taken together, these results indicate that the up-regulated expression of Oct-4 in LC-CD133+ may contribute to the development of chemoradioresistance in patients with lung cancer.
###end p 64
###begin p 65
###xml 350 354 350 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Elkind1">[41]</xref>
###xml 356 360 356 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Kawabata1">[43]</xref>
###xml 635 639 635 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-HirschmannJax1">[44]</xref>
###xml 823 827 823 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002637-Monzani1">[45]</xref>
###xml 866 867 866 867 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1003 1004 1003 1004 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1006 1013 1006 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g002">Figs. 2</xref>
###xml 1016 1017 1016 1017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002637-g004">4</xref>
###xml 1136 1137 1136 1137 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1359 1360 1359 1360 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 38 43 <span type="species:ncbi:9606">human</span>
###xml 324 332 <span type="species:ncbi:9606">patients</span>
###xml 493 501 <span type="species:ncbi:9606">patients</span>
###xml 1409 1417 <span type="species:ncbi:9606">patients</span>
Recent studies have revealed that the human ABCG2 transporter is a P-glycoprotein that causes multidrug resistance (MDR) including mitoxantrone, doxorubicin, and topoisomerase I inhibitors of irinotecan, topotecan, and 7-ethyl-10-hydroxycamptothecin (topoisomerase inhibitor) and gefitinib (an inhibitor of EGF receptor) in patients with lung cancer [41], [43]. Hirschmann-Jax and colleagues were the first to observe that "side population" cancer stem-like cells isolated from cell lines and patients with neuroblastoma expressed high levels of ABCG2 and ABCG3 transporter genes as well as a greater capacity to expel cytotoxic drugs [44]. Monzani and colleagues further showed that cancer stem-like cells derived from the melanoma cell line highly co-expressed CD133 and ABCG2 markers with enhanced tumorigenic potential [45]. In this study, we found that LC-CD133+ are highly co-expressed with ABCG2 transporter and are significantly resistant to conventional treatment methods compared with LC-CD133- (Figs. 2 & 4). Interestingly, a significant down-regulating of ABCG2 expression and an increase in the chemosensitivity of LC-CD133+ were observed when the Oct-4 siRNA treatment was given (Data not shown). Thus, more studies are needed to investigate whether over-expression of Oct-4, CD133, and/or ABCG2 play a role in the development of MDR in LC-CD133+ or surrogate markers of therapeutic response in patients with lung cancer.
###end p 65
###begin p 66
###xml 44 45 44 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 241 242 241 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 246 254 246 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 259 266 259 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 527 535 <span type="species:ncbi:9606">patients</span>
In conclusion, we demonstrated that LC-CD133+ display a higher Oct-4 expression with the ability to self-renew and may represent a reservoir with unlimited proliferative potentials for generating lung cancer cells. The resistance of LC-CD133+ to in vitro and in vivo chemoradiotherapy is partially due to preferential activation of Oct-4 gene expression. In addition, these data support that the up-regulated expressions of the Oct-4, self-renewing gene of embryonic stem cells, play an important role in the tumorigenicity of patients with lung cancer.
###end p 66
###begin title 67
Supporting Information
###end title 67
###begin p 68
(0.05 MB DOC)
###end p 68
###begin p 69
Click here for additional data file.
###end p 69
###begin p 70
###xml 89 97 <span type="species:ncbi:9606">patients</span>
###xml 175 183 <span type="species:ncbi:9606">patients</span>
###xml 546 554 <span type="species:ncbi:9606">patients</span>
###xml 629 637 <span type="species:ncbi:9606">patients</span>
Correlation of Oct-4 expression levels and the clinical grading and survival rate in the patients with lung cancers. (A) Detection of Oct-4 expression in 78 NSCLC lung cancer patients with different stages by using immunohistochemistry (IHC). Black arrows: positive signals for Oct-4 by IHC. Bar: 50 um. (B) Oct-4 was detected in the almost high grades (III & IV) of lung cancer tissues, and significantly expressed the higher intensity of Oct-4-positive signals in grade III & IV (high grade) than those in grade I & II (low grade) lung cancers patients (p<0.01). (C) Kaplan-Meier analysis of overall survival in 78 lung cancer patients with or without Oct-4 expression.
###end p 70
###begin p 71
(7.61 MB TIF)
###end p 71
###begin p 72
Click here for additional data file.
###end p 72
###begin title 73
References
###end title 73
###begin article-title 74
Multidisciplinary management of lung cancer.
###end article-title 74
###begin article-title 75
Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer.
###end article-title 75
###begin article-title 76
Limited-stage small-cell lung cancer: the current status of combined-modality therapy.
###end article-title 76
###begin article-title 77
Chemotherapy and radiotherapy in the treatment of resectable non-small-cell lung cancer.
###end article-title 77
###begin article-title 78
Lung cancer: future directions.
###end article-title 78
###begin article-title 79
Cancer stem cells.
###end article-title 79
###begin article-title 80
###xml 39 45 <span type="species:ncbi:10090">murine</span>
Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo.
###end article-title 80
###begin article-title 81
###xml 19 24 <span type="species:ncbi:9606">human</span>
Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells.
###end article-title 81
###begin article-title 82
Identification of uPAR-positive chemoresistant cells in small cell lung cancer.
###end article-title 82
###begin article-title 83
###xml 26 31 <span type="species:ncbi:9606">human</span>
AC133, a novel marker for human hematopoietic stem and progenitor cells.
###end article-title 83
###begin article-title 84
Prospective identification of tumorigenic prostate cancer stem cells.
###end article-title 84
###begin article-title 85
Detection of tumor stem cell markers in pancreatic carcinoma cell lines.
###end article-title 85
###begin article-title 86
###xml 2 7 <span type="species:ncbi:9606">human</span>
###xml 81 85 <span type="species:ncbi:10090">mice</span>
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice.
###end article-title 86
###begin article-title 87
Identification and characterization of tumorigenic liver cancer stem/progenitor cells.
###end article-title 87
###begin article-title 88
###xml 40 45 <span type="species:ncbi:9606">human</span>
Identification of a cancer stem cell in human brain tumors.
###end article-title 88
###begin article-title 89
###xml 18 23 <span type="species:ncbi:9606">human</span>
Identification of human brain tumour initiating cells.
###end article-title 89
###begin article-title 90
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.
###end article-title 90
###begin article-title 91
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.
###end article-title 91
###begin article-title 92
CD133+ renal progenitor cells contribute to tumor angiogenesis.
###end article-title 92
###begin article-title 93
CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer.
###end article-title 93
###begin article-title 94
Identification and expansion of the tumorigenic lung cancer stem cell population.
###end article-title 94
###begin article-title 95
A POU-domain transcription factor in early stem cells and germ cells of the mammalian embryo.
###end article-title 95
###begin article-title 96
Signalling, cell cycle and pluripotency in embryonic stem cells.
###end article-title 96
###begin article-title 97
Regulatory networks in embryo-derived pluripotent stem cells.
###end article-title 97
###begin article-title 98
Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4.
###end article-title 98
###begin article-title 99
Effects of differentiation on the transcriptional regulation of the FGF-4 gene: critical roles played by a distal enhancer.
###end article-title 99
###begin article-title 100
###xml 91 96 <span type="species:ncbi:9606">human</span>
Oct-4 regulates alternative platelet-derived growth factor alpha receptor gene promoter in human embryonal carcinoma cells.
###end article-title 100
###begin article-title 101
Identification of CD133-positive Radioresistant Cells in Atypical Teratoid/Rhabdoid Tumor.
###end article-title 101
###begin article-title 102
Direct regulation of TWIST by HIF-1alpha promotes metastasis.
###end article-title 102
###begin article-title 103
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.
###end article-title 103
###begin article-title 104
Generation of germline-competent induced pluripotent stem cells.
###end article-title 104
###begin article-title 105
###xml 17 22 <span type="species:ncbi:9606">human</span>
Reprogramming of human somatic cells to pluripotency with defined factors.
###end article-title 105
###begin article-title 106
###xml 49 54 <span type="species:ncbi:9606">human</span>
Induced pluripotent stem cell lines derived from human somatic cells.
###end article-title 106
###begin article-title 107
###xml 102 118 <span type="species:ncbi:227859">SARS coronavirus</span>
Identification of pulmonary Oct-4+ stem/progenitor cells and demonstration of their susceptibility to SARS coronavirus (SARS- CoV) infection in vitro.
###end article-title 107
###begin article-title 108
###xml 47 52 <span type="species:ncbi:9606">human</span>
Examination of POU homeobox gene expression in human breast cancer cells.
###end article-title 108
###begin article-title 109
###xml 116 121 <span type="species:ncbi:9606">human</span>
The POU homeodomain protein OCT3 as a potential transcriptional activator for fibroblast growth factor-4 (FGF-4) in human breast cancer cells.
###end article-title 109
###begin article-title 110
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human embryonic genes re-expressed in cancer cells.
###end article-title 110
###begin article-title 111
Oct-3/4 is a dose-dependent oncogenic fate determinant.
###end article-title 111
###begin article-title 112
Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties.
###end article-title 112
###begin article-title 113
Cancer Stem Cells-Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem Cells.
###end article-title 113
###begin article-title 114
Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).
###end article-title 114
###begin article-title 115
###xml 48 54 <span type="species:ncbi:10090">murine</span>
Oct-4 is critical for survival/antiapoptosis of murine embryonic stem cells subjected to stress: effects associated with Stat3/survivin.
###end article-title 115
###begin article-title 116
Expression and functional analyses of breast cancer resistance protein in lung cancer.
###end article-title 116
###begin article-title 117
###xml 72 77 <span type="species:ncbi:9606">human</span>
A distinct "side population" of cells with high drug efflux capacity in human tumor cells.
###end article-title 117
###begin article-title 118
Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential.
###end article-title 118
###begin p 119
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 119
###begin p 120
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
###xml 317 321 <span type="species:ncbi:163112">Ling</span>
Funding: This study was supported by research grants from the National Science Council (NSC-96-3111-B-075-001-MY3, 95-2314-B-075-055-MY2, 96-2628-B-010-006-MY3, 96-2314-B-075-024), Taipei Veterans General Hospital (V96C1-151, V96E1-004, V96ER2-016, V96E2-010), the Joint Projects of UTVGH (VGHUST96-P1-07), Yen-Tjing-Ling Medical Foundation, Taipei City Hospital (96001-62-014, 96001-62-018, 96002-62-092), and National Yang-Ming University (Ministry of Education, Aim for the Top University Plan), Taiwan.
###end p 120

